These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 9710694)

  • 1. Expression of cathepsin D and pS2 in imprint smears of breast carcinoma.
    Athanassiadou PP; Athanassiades PH; Davaris P; Petrakakou EI; Zerva CI; Kyrkou KA
    Cytopathology; 1998 Aug; 9(4):240-7. PubMed ID: 9710694
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunoradiometric detection of pS2 and total cathepsin D in primary breast cancer biopsies: their correlation with steroid receptors.
    Marsigliante S; Biscozzo L; Correale M; Paradiso A; Leo G; Abbate I; Dragone CD; Storelli C
    Br J Cancer; 1994 Mar; 69(3):550-4. PubMed ID: 8123486
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic value of PS2 and cathepsin D in 710 human primary breast tumors: multivariate analysis.
    Foekens JA; van Putten WL; Portengen H; de Koning HY; Thirion B; Alexieva-Figusch J; Klijn JG
    J Clin Oncol; 1993 May; 11(5):899-908. PubMed ID: 8487052
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estrogen-regulated cut-off values of pS2 and cathepsin D expression in breast carcinomas.
    Markićević M; Petrović A; Kanjer K; Nesković-Konstantinović Z; Nikolić-Vukosavujević D
    Adv Exp Med Biol; 2008; 617():341-8. PubMed ID: 18497057
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinicopathological study of the expression of hsp27, pS2, cathepsin D and metallothionein in primary invasive breast cancer.
    Ioachim E; Tsanou E; Briasoulis E; Batsis Ch; Karavasilis V; Charchanti A; Pavlidis N; Agnantis NJ
    Breast; 2003 Apr; 12(2):111-9. PubMed ID: 14659340
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationships between cathepsin-D, pS2 protein and hormonal receptors in breast cancer cytosols: inconsistency with their established prognostic significance.
    Ardavanis A; Gerakini F; Amanatidou A; Scorilas A; Pateras C; Garoufali A; Pissakas G; Stravolemos K; Apostolikas N; Yiotis I
    Anticancer Res; 1997; 17(5A):3665-9. PubMed ID: 9413220
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Messenger RNA determination of estrogen receptor, progesterone receptor, pS2, and plasminogen activator inhibitor-1 by competitive reverse transcription-polymerase chain reaction in human breast cancer.
    Tong D; Schneeberger C; Czerwenka K; Schmutzler RK; Speiser P; Kucera E; Concin N; Kubista E; Leodolter S; Zeillinger R
    Clin Cancer Res; 1999 Jun; 5(6):1497-502. PubMed ID: 10389938
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Steroid receptors, pS2 and cathepsin D in early clinically node-negative breast cancer.
    Stonelake PS; Baker PG; Gillespie WM; Dunn JA; Spooner D; Morrison JM; Bundred NJ; Oates GD; Lee MJ; Neoptolemos JP
    Eur J Cancer; 1994; 30A(1):5-11. PubMed ID: 8142164
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of ER, PR, MIB-1, pS2, and nuclear grade in FNA specimens of cT1 breast carcinomas: clinicopathological correlation.
    Angelidou E; Politi E; Sotiropoulou G; Poulianou E; Koutselini H
    Diagn Cytopathol; 2006 Aug; 34(8):547-52. PubMed ID: 16850494
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oestrogen receptor, progesterone receptor, pS2, ERD5, HSP27 and cathepsin D in invasive ductal breast carcinomas.
    Hurlimann J; Gebhard S; Gomez F
    Histopathology; 1993 Sep; 23(3):239-48. PubMed ID: 8225242
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of pS2, c-erbB-2, and cathepsin D during the menstrual cycle in human breast cancers.
    Khan SA; Gonchoroff NJ; Miller LE
    Ann Surg Oncol; 1997 Sep; 4(6):462-9. PubMed ID: 9309334
    [TBL] [Abstract][Full Text] [Related]  

  • 12. pS2 (TFF1) levels in human breast cancer tumor samples: correlation with clinical and histological prognostic markers.
    Gillesby BE; Zacharewski TR
    Breast Cancer Res Treat; 1999 Aug; 56(3):253-65. PubMed ID: 10573116
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic significance of the estrogen-regulated proteins, cathepsin-D and pS2, in breast cancer.
    Fulco RA; Petix M; Salimbeni V; Torre EA
    Minerva Med; 1998; 89(1-2):5-10. PubMed ID: 9561019
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Value of immunohistochemical determination of receptors, tissue proteases, tumor suppressor proteins and proliferation markers as prognostic indicators in primary breast carcinoma].
    Göhring UJ; Scharl A; Ahr A
    Geburtshilfe Frauenheilkd; 1996 Apr; 56(4):177-83. PubMed ID: 8682282
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Time at surgery during menstrual cycle and menopause affects pS2 but not cathepsin D levels in breast cancer.
    Pujol P; Daurès JP; Brouillet JP; Maudelonde T; Rochefort H; Grenier J
    Br J Cancer; 1999 Feb; 79(5-6):909-14. PubMed ID: 10070889
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of ER, PR and HER-2/neu (C-erb B 2) reactivity pattern with histologic grade, tumor size and lymph node status in breast cancer.
    Azizun-Nisa ; Bhurgri Y; Raza F; Kayani N
    Asian Pac J Cancer Prev; 2008; 9(4):553-6. PubMed ID: 19256737
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of pS2 protein and estrogen and progesterone receptor status in breast cancer.
    Ioakim-Liossi A; Karakitsos P; Markopoulos C; Aroni K; Delivelioti K; Gogas J; Kyrkou K
    Acta Cytol; 1997; 41(3):713-6. PubMed ID: 9167689
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inflammatory breast carcinoma: an immunohistochemical study using monoclonal anti-pHER-2/neu, pS2, cathepsin, ER and PR.
    Charpin C; Bonnier P; Khouzami A; Vacheret H; Andrac L; Lavaut MN; Allasia C; Piana L
    Anticancer Res; 1992; 12(3):591-7. PubMed ID: 1352440
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Immunohistochemical detection of pS2 protein in paraffin sections of breast carcinoma tissue. Comparison with results of an immunoradiometry assay].
    Ahr A; Scharl A; Göhring UJ; Crombach G; Stoffl M
    Pathologe; 1995 Jul; 16(4):278-84. PubMed ID: 7667210
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PS2 in breast cancer--alternative or complementary tool to steroid receptor status? Evaluation of 446 cases.
    Gion M; Mione R; Pappagallo GL; Gatti C; Nascimben O; Bari M; Leon AE; Vinante O; Bruscagnin G
    Br J Cancer; 1993 Aug; 68(2):374-9. PubMed ID: 8347494
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.